Non‐pharmacological interventions for anxiety and depression in Parkinson's disease Authors: Tengfei Li, Jiyuan Shi, Qingyong Zheng, Jian-Guo Xu, Mingyue Zhang, Yalin Ren, BoWa Zhang, Zheng Li Published: 2026 ABSTRACT ObjectivesThis is a protocol for a Cochrane Review (intervention). The objectives are as follows:To evaluate and compare the efficacy and safety of non‐pharmacological interventions for reducing symptoms of anxiety and depression in individuals with Parkinson’s disease. Background Description of the condition Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide [1]. By 2050, an estimated 25.2 million people are expected to be living with PD globally, representing a 112% increase from 2021 [2]. According to the World Health Organization (WHO), neurodegenerative diseases—including PD and Alzheimer’s disease—are projected to become the second leading cause of death worldwide by 2040, surpassing cancer‐related mortality [3]. The clinical hallmark of PD is a motor syndrome characterized by resting tremor, rigidity, bradykinesia, and postural instability [4]. PD is also associated with numerous non‐motor symptoms—such as neuropsychiatric disturbances, cognitive impairment, sleep disorders, and autonomic dysfunction—that severely impair patients’ overall functioning [5]. Anxiety and depression, which frequently co‐occur, affect approximately 40% to 50% of individuals with PD [6]. These conditions are associated with increased care dependency, impaired occupational and social functioning, accelerated physical and cognitive decline, elevated dementia risk, and higher mortality rates [7, 8]. Anxiety and depression in PD may result from PD‐related abnormalities in brain circuits that depend on dopamine, serotonin, and noradrenaline. These abnormalities particularly involve the limbic cortico‐striato‐thalamo‐cortical pathway and the 'fear' circuit, in which the amygdala plays a central role [9, 10]. Research indicates that people with late‐onset PD experience milder depressive symptoms compared to those with early‐onset PD [11]. Females with PD have a younger mean age at onset and more severe anxiety and depressive symptoms compared to males with PD [11]. Depressive and anxiety symptoms increase disproportionately with age in women compared with men [12]. Regarding intervention characteristics, duration and intensity may modulate effectiveness [13]. In addition, medication‐related factors may influence intervention outcomes [14]. Description of the intervention and how it might work The clinical management of anxiety and depression in PD currently involves both pharmacological and non‐pharmacological approaches. However, pharmacological treatments are often poorly tolerated, may demonstrate limited efficacy, and can cause undesirable side effects [15]. In addition, their use is complicated by the high prevalence of polypharmacy among people with PD [16]. Non‐pharmacological interventions should therefore be considered as potential alternatives or adjuncts to existing pharmacological and neurosurgical therapies. A wide range of non‐pharmacological interventions have been employed to alleviate anxiety and depression in individuals with PD. These interventions can be broadly categorized as follows: psychological therapies, including cognitive behavioral therapy (CBT); non‐invasive brain stimulation (NIBS) techniques, such as repetitive transcranial magnetic stimulation (rTMS) and transcranial direct current stimulation (tDCS); exercise‐based interventions, including aerobic, resistance, and balance training; and complementary therapies, such as tai chi, qigong, yoga, meditation, acupuncture, auricular acupressure, massage, music therapy, bright light therapy (BLT), and dance therapy. Psychological therapies are considered the gold standard for treating depressive and anxiety disorders. CBT is an umbrella term encompassing a range of therapeutic approaches based on cognitive and behavioral conditioning theories [17]. The use of CBT to treat depression and anxiety in individuals with PD has become increasingly widespread in clinical practice. A previous systematic review demonstrated that CBT significantly alleviates anxiety and depressive symptoms in individuals with PD compared with waiting‐list or treatment‐as‐usual control groups [18]. However, the neural mechanisms underlying CBT’s effects on anxiety and depression in PD remain largely unclear. It has been hypothesized that CBT exerts its therapeutic effects by strengthening brain circuits involved in cognitive control (frontoparietal network), emotion regulation, and response inhibition (cortico‐striato‐thalamo‐cortical circuits) [19]. NIBS techniques, such as rTMS and tDCS, have emerged as promising non‐pharmacological interventions for managing both motor and non‐motor symptoms in PD. Zheng and colleagues reported that NIBS was significantly more effective than sham stimulation or placebo in alleviating depressive symptoms in individuals with PD. Furthermore, rTMS combined with antidepressant therapy was found to be significantly more effective than antidepressant monotherapy in improving both depressive and anxiety symptoms in PD [20]. By targeting specific cortical regions that serve as ‘entry points’ to relevant neural circuits, rTMS and tDCS may normalize cortical excitability, modulate activity in interconnected brain regions, enhance brain network connectivity, and promote neuroplasticity [21, 22]. The therapeutic effects of NIBS on depression and anxiety are thought to result from the modulation of dysfunctional neural circuits involved in mood regulation, anxiety control, and cognitive processing [21, 22]. Exercise‐based interventions, alone or combined with other non‐pharmacological approaches, may effectively reduce depressive symptoms in individuals with PD. Feller and colleagues reported that exercise training produced significant improvements in depressive symptoms compared with usual care [23]. However, evidence supporting the effects of exercise on anxiety in PD is less robust. Ferreira and colleagues found that 24 weeks of resistance training significantly reduced anxiety levels and improved quality of life [24], whereas Wu and colleagues reported that low‐dose, home‐based exercise was not effective in reducing anxiety [25]. Exercise is also hypothesized to influence neurostructural and neurochemical processes in PD. Studies indicate that comorbid depression or anxiety in PD is associated with abnormalities in inflammatory cytokine expression, receptor availability, neurotrophin levels, brain volume and connectivity, and the availability of dopamine, norepinephrine, and serotonin [26]. It has been hypothesized that exercise may positively modulate these structural and neurochemical processes [26, 27]. Complementary therapies are non‐mainstream practices used alongside conventional medical treatments [28]. Survey‐based studies conducted before 2013 reported that 26% to 76% of individuals with PD used complementary therapies to manage various symptoms across different countries [29]. Li and colleagues found that acupuncture significantly improved depressive symptoms in PD [30]. In contrast, Yang and colleagues reported that tai chi did not significantly improve depressive symptoms in individuals with PD [31]. Kwok and colleagues assessed the effects of yoga on anxiety and depression using the Hospital Anxiety and Depression Scale (HADS) and found that yoga significantly improved both anxiety and depressive symptoms in PD [32]. These improvements may be attributed to an enhanced internal locus of control, reflecting the extent to which patients believe they can influence their own health. Greater engagement in treatment often leads to increased optimism, reduced depressive symptoms, and improved quality of life [33]. BLT is an attractive treatment option as it has few contraindications and side effects. Sun and colleagues indicated that individuals with idiopathic PD who received BLT experienced significant improvements in depressive symptoms and sleep disturbance scores [34]. In PD, circadian rhythms can become disrupted due to multiple factors, which may contribute to both depressive symptoms and sleep disturbances [35]. BLT involves daily, rhythmic exposure to light‐emitting devices, which restores circadian rhythms by stimulating the suprachiasmatic nucleus through retinal melanopsin‐containing cells, thereby reducing depressive symptoms and improving sleep quality [17]. Why it is important to do this review Most randomized controlled trials (RCTs) have compared non‐pharmacological interventions with placebo, waiting‐list controls, or usual care [24, 25, 36, 37, 38, 39, 40, 41, 42, 43]. However, a limited number of RCTs have directly compared two different non‐pharmacological interventions [32, 44, 45, 46, 47]. Consequently, the relative effectiveness of different non‐pharmacological interventions remains unclear. Moreover, previous systematic reviews have assessed the effects of various non‐pharmacological interventions on anxiety and depression in individuals with PD; however, several of these systematic reviews included non‐RCTs or lacked quantitative analyses [48, 49, 50], thereby providing limited high‐quality evidence. Wang and colleagues conducted a systematic review evaluating the effects of 35 non‐pharmacological interventions on depressive symptoms in individuals with PD [51]. However, the systematic review had several limitations. First, it did not simultaneously assess both anxiety and depression, which often co‐occur in PD. In fact, systematic reviews focusing specifically on anxiety remain scarce, leading to limited evidence regarding the effects of non‐pharmacological interventions on anxiety. Second, it did not include high‐quality RCTs published after April 2022, despite a substantial number of relevant studies being conducted in recent years. Third, from a methodological perspective, the systematic review did not apply the GRADE approach to assess the quality of evidence, limiting the credibility of its conclusions. Finally, the systematic review did not incorporate patient and public involvement, thus lacking consideration of the needs and values of the target population. It is therefore essential to conduct a systematic review and network meta‐analysis to comprehensively summarize the current evidence. This study aims to assess and compare the efficacy and safety of different non‐pharmacological interventions for anxiety and depression in individuals with PD, providing evidence‐based guidance for clinical practice. Objectives To evaluate and compare the efficacy and safety of non‐pharmacological interventions for reducing symptoms of anxiety and depression in individuals with Parkinson’s disease. Methods Criteria for considering studies for this review Types of studies We will include parallel, cross‐over, and cluster RCTs that compare any non‐pharmacological intervention with placebo, no treatment, or another non‐pharmacological intervention. We will include cross‐over trials only if they provide an adequate washout period (≥ 2 weeks); otherwise, we will analyze only the data from the first treatment period. We will exclude RCTs that compare different methods of the same intervention. Types of participants We will include studies involving participants diagnosed with PD who have anxiety or depression, without restrictions on age, gender, race, nationality, education level, disease stage, or disease duration. The diagnosis of anxiety or depression will include both professional diagnoses made by qualified medical personnel using standardized diagnostic criteria—such as the Diagnostic and Statistical Manual of Mental Disorders, Fourth or Fifth Edition (DSM‐IV/V), or the International Classification of Diseases, 11th Revision (ICD‐11)—and self‐reported cases from participants. We will include studies in which participants are assessed using validated anxiety or depression scales. Types of interventions We will include RCTs evaluating non‐pharmacological interventions for anxiety or depression, regardless of intervention frequency, duration, mode, period, format, or setting, compared with placebo, waiting‐list controls, usual care, or other non‐pharmacological interventions. We will consider the following non‐pharmacological interventions: psychological therapies, including CBT; non‐invasive brain stimulation (rTMS and tDCS); exercise therapy, including aerobic exercise, resistance exercise, and balance training; and complementary therapies, such as tai chi, qigong, yoga, meditation, acupuncture, auricular pressure, massage, music therapy, BLT, and dance therapy. We have classified the interventions a priori and will adjust this classification if we detect any lack of transitivity. Outcome measures We will present results separately for short‐term (≤ 6 months) and long‐term (> 6 months) follow‐up, if data are available. When multiple assessments are reported within this interval, we will use the assessment closest to the end of the intervention. Critical outcomes We will assess the efficacy of interventions for anxiety and depression in PD using standardized and validated rating scales. We will prioritize scales according to a predefined hierarchy to ensure consistency across studies, as follows. Anxiety:Hamilton Anxiety Rating Scale (HARS) [52]Beck Anxiety Inventory (BAI) [53]State‐Trait Anxiety Inventory (STAI) [54]Zung Self‐Rating Anxiety Scale (SAS) [55]Generalized Anxiety Disorder (GAD) [56]Hospital Anxiety and Depression Scale (HADS) [57]Depression:Hamilton Depression Rating Scale (HDRS) [58]Beck Depression Inventory (BDI) [59]Montgomery‐Asberg Depression Rating Scale (MADRS) [60]Zung Self‐Rating Depression Scale (SDS) [61]Geriatric Depression Scale (GDS) [62]Patient Health Questionnaire (PHQ) [63]Hospital Anxiety and Depression Scale (HADS) [57] Anxiety:Hamilton Anxiety Rating Scale (HARS) [52]Beck Anxiety Inventory (BAI) [53]State‐Trait Anxiety Inventory (STAI) [54]Zung Self‐Rating Anxiety Scale (SAS) [55]Generalized Anxiety Disorder (GAD) [56]Hospital Anxiety and Depression Scale (HADS) [57] Anxiety: Hamilton Anxiety Rating Scale (HARS) [52] Hamilton Anxiety Rating Scale (HARS) [52] Beck Anxiety Inventory (BAI) [53] Beck Anxiety Inventory (BAI) [53] State‐Trait Anxiety Inventory (STAI) [54] State‐Trait Anxiety Inventory (STAI) [54] Zung Self‐Rating Anxiety Scale (SAS) [55] Zung Self‐Rating Anxiety Scale (SAS) [55] Generalized Anxiety Disorder (GAD) [56] Generalized Anxiety Disorder (GAD) [56] Hospital Anxiety and Depression Scale (HADS) [57] Hospital Anxiety and Depression Scale (HADS) [57] Depression:Hamilton Depression Rating Scale (HDRS) [58]Beck Depression Inventory (BDI) [59]Montgomery‐Asberg Depression Rating Scale (MADRS) [60]Zung Self‐Rating Depression Scale (SDS) [61]Geriatric Depression Scale (GDS) [62]Patient Health Questionnaire (PHQ) [63]Hospital Anxiety and Depression Scale (HADS) [57] Depression: Hamilton Depression Rating Scale (HDRS) [58] Hamilton Depression Rating Scale (HDRS) [58] Beck Depression Inventory (BDI) [59] Beck Depression Inventory (BDI) [59] Montgomery‐Asberg Depression Rating Scale (MADRS) [60] Montgomery‐Asberg Depression Rating Scale (MADRS) [60] Zung Self‐Rating Depression Scale (SDS) [61] Zung Self‐Rating Depression Scale (SDS) [61] Geriatric Depression Scale (GDS) [62] Geriatric Depression Scale (GDS) [62] Patient Health Questionnaire (PHQ) [63] Patient Health Questionnaire (PHQ) [63] Hospital Anxiety and Depression Scale (HADS) [57] Hospital Anxiety and Depression Scale (HADS) [57] We will assess safety by documenting the incidence and type of adverse effects or events following non‐pharmacological interventions for anxiety or depression in individuals with PD. Important outcomes We will assess changes in health‐related quality of life, cognitive function, and motor symptoms using validated scales or questionnaires. We will prioritize them according to a predefined hierarchy to ensure consistency across studies, as follows. Health‐related quality of life:Parkinson’s Disease Questionnaire–39 items (PDQ‐39) [64]Parkinson’s Disease Questionnaire–8 items (PDQ‐8) [65]Cognitive function:Mini Mental State Examination (MMSE) [66]Montreal Cognitive Assessment (MoCA) [67]Motor symptoms:Movement Disorder Society‐Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS) [68]Unified Dyskinesia Rating Scale (UDysRS) [69]Rush Dyskinesia Rating Scale (RDRS) [70] Health‐related quality of life:Parkinson’s Disease Questionnaire–39 items (PDQ‐39) [64]Parkinson’s Disease Questionnaire–8 items (PDQ‐8) [65] Health‐related quality of life: Parkinson’s Disease Questionnaire–39 items (PDQ‐39) [64] Parkinson’s Disease Questionnaire–39 items (PDQ‐39) [64] Parkinson’s Disease Questionnaire–8 items (PDQ‐8) [65] Parkinson’s Disease Questionnaire–8 items (PDQ‐8) [65] Cognitive function:Mini Mental State Examination (MMSE) [66]Montreal Cognitive Assessment (MoCA) [67] Cognitive function: Mini Mental State Examination (MMSE) [66] Mini Mental State Examination (MMSE) [66] Montreal Cognitive Assessment (MoCA) [67] Montreal Cognitive Assessment (MoCA) [67] Motor symptoms:Movement Disorder Society‐Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS) [68]Unified Dyskinesia Rating Scale (UDysRS) [69]Rush Dyskinesia Rating Scale (RDRS) [70] Motor symptoms: Movement Disorder Society‐Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS) [68] Movement Disorder Society‐Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS) [68] Unified Dyskinesia Rating Scale (UDysRS) [69] Unified Dyskinesia Rating Scale (UDysRS) [69] Rush Dyskinesia Rating Scale (RDRS) [70] Rush Dyskinesia Rating Scale (RDRS) [70] Search methods for identification of studies Electronic searches We will develop our search strategy following the best practices outlined in Chapter 4 of the Cochrane Handbook for Systematic Reviews of Interventions [71]. We will search all databases using controlled vocabulary (e.g. MeSH in MEDLINE and Emtree in Embase) combined with a broad range of free‐text terms Supplementary material 1. We will search the following electronic databases without restrictions on language or publication status: Cochrane Central Register of Controlled Trials (CENTRAL) accessed via the Cochrane Library;MEDLINE accessed via PubMed (1946 to present);Embase accessed via Embase.com (1947 to present);Web of Science (1900 to present). Cochrane Central Register of Controlled Trials (CENTRAL) accessed via the Cochrane Library; Cochrane Central Register of Controlled Trials (CENTRAL) accessed via the Cochrane Library; MEDLINE accessed via PubMed (1946 to present); MEDLINE accessed via PubMed (1946 to present); Embase accessed via Embase.com (1947 to present); Embase accessed via Embase.com (1947 to present); Web of Science (1900 to present). Web of Science (1900 to present). We will also search the following clinical trials registries to identify unpublished and ongoing trials: World Health Organization International Clinical Trials Registry Platform (trialsearch.who.int/);US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (clinicaltrials.gov/);EU Clinical Trials Register (www.clinicaltrialsregister.eu/);ISRCTN registry (www.isrctn.com/). World Health Organization International Clinical Trials Registry Platform (trialsearch.who.int/); World Health Organization International Clinical Trials Registry Platform (trialsearch.who.int/); US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (clinicaltrials.gov/); US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (clinicaltrials.gov/); EU Clinical Trials Register (www.clinicaltrialsregister.eu/); EU Clinical Trials Register (www.clinicaltrialsregister.eu/); ISRCTN registry (www.isrctn.com/). ISRCTN registry (www.isrctn.com/). For studies published in languages not spoken by the review team, we will initially use machine translation tools, such as Google Translate or DeepL, to screen titles and abstracts and to extract preliminary data. For full‐text articles or when machine translation proves insufficient, we will engage professional translation services or seek assistance from collaborators fluent in the target language to accurately extract and interpret the relevant data. Searching other resources We will review the reference lists of identified trials and systematic reviews and obtain the full texts of trials that appear potentially eligible. If full texts are inaccessible, we will contact study authors to request additional information. We will conduct a targeted search to determine whether any included studies have undergone post‐publication amendments, including errata, retractions, or expressions of concern. For each eligible study, we will search the Retraction Watch Database, review any amendments listed in primary databases (e.g. MEDLINE, Embase), and check relevant journal websites. We will clearly document any identified studies and assess their potential impact on the conclusions of the review. We will also search conference abstracts from the following sources. International Congress of Parkinson's Disease & Movement Disorders (www.mdscongress.org/)American Academy of Neurology (www.aan.com/)European Academy of Neurology (www.ean.org/)International Association of Parkinsonism and Related Disorders (iaprd‐parkinson.org/) International Congress of Parkinson's Disease & Movement Disorders (www.mdscongress.org/) International Congress of Parkinson's Disease & Movement Disorders (www.mdscongress.org/) American Academy of Neurology (www.aan.com/) American Academy of Neurology (www.aan.com/) European Academy of Neurology (www.ean.org/) European Academy of Neurology (www.ean.org/) International Association of Parkinsonism and Related Disorders (iaprd‐parkinson.org/) International Association of Parkinsonism and Related Disorders (iaprd‐parkinson.org/) Data collection and analysis Selection of studies We will use EndNote X9 software to manage and remove duplicate records [72]. Two review authors (TFL and JYS) will independently select studies for inclusion according to the methods described in the Cochrane Handbook for Systematic Reviews of Interventions [71], following the steps listed below. Screen the titles and abstracts of all records to exclude studies that clearly do not meet the inclusion criteria.Retrieve the full texts of potentially relevant reports and link multiple reports of the same study.Assess the full texts for compliance with the eligibility criteria.Contact study investigators, if necessary, to clarify eligibility and request additional information, such as missing methods or results. If studies remain incomplete or unobtainable, we will record them as incomplete and classify them as studies awaiting classification.Cross‐check selections and resolve any disagreements through discussion, or consult a third review author (ZL) if necessary.Make final decisions regarding study inclusion. Screen the titles and abstracts of all records to exclude studies that clearly do not meet the inclusion criteria. Screen the titles and abstracts of all records to exclude studies that clearly do not meet the inclusion criteria. Retrieve the full texts of potentially relevant reports and link multiple reports of the same study. Retrieve the full texts of potentially relevant reports and link multiple reports of the same study. Assess the full texts for compliance with the eligibility criteria. Assess the full texts for compliance with the eligibility criteria. Contact study investigators, if necessary, to clarify eligibility and request additional information, such as missing methods or results. If studies remain incomplete or unobtainable, we will record them as incomplete and classify them as studies awaiting classification. Contact study investigators, if necessary, to clarify eligibility and request additional information, such as missing methods or results. If studies remain incomplete or unobtainable, we will record them as incomplete and classify them as studies awaiting classification. Cross‐check selections and resolve any disagreements through discussion, or consult a third review author (ZL) if necessary. Cross‐check selections and resolve any disagreements through discussion, or consult a third review author (ZL) if necessary. Make final decisions regarding study inclusion. Make final decisions regarding study inclusion. We will document the reasons for excluding ineligible studies in the ‘Characteristics of excluded studies’ table. We will also record ongoing trials that have not yet been reported so they can be included as ongoing studies. Additionally, we will use the PRISMA flow diagram to record the study screening and updating process. Data extraction and management Two review authors (JYS and QYZ) will independently extract relevant data from the included studies, which a third review author (JGX) will verify. We will resolve any disagreements by consensus following the methods described in the Cochrane Handbook for Systematic Reviews of Interventions [73]. We will develop a standardized data extraction form and collect the following information from each included study. General information: study title, year of publication, journal, study name, funding sources, and contact details.Study methodology: study design, randomization procedures, number of study centers and locations, study setting, study dates, treatments received prior to the study, and treatments administered during the study.Participant characteristics: sample size, mean age, gender, diagnostic criteria, and disease duration; whether participants were on stable antiparkinsonian medication regimens at baseline; timing of outcome assessments relative to medication cycles (e.g. defined 'on' or 'off' states); and use and stability of psychotropic medications.Intervention characteristics: name of the intervention, number of participants randomized to each intervention, frequency, formulation, and duration.Outcomes: primary and secondary outcomes with definitions and time points. For dichotomous data (e.g. adverse events), we will extract the number of participants in each treatment arm who experienced the outcome and the total assessed at the endpoint. For continuous data (e.g. anxiety, depression, health‐related quality of life), we will extract the baseline and final values, standard deviations (SDs), and number of participants assessed in each arm at the endpoint.Results: the number of participants allocated to each group, total number analyzed per outcome, group‐level summary data, and the use of intention‐to‐treat (ITT) or per‐protocol (PP) analysis methods. General information: study title, year of publication, journal, study name, funding sources, and contact details. General information: study title, year of publication, journal, study name, funding sources, and contact details. Study methodology: study design, randomization procedures, number of study centers and locations, study setting, study dates, treatments received prior to the study, and treatments administered during the study. Study methodology: study design, randomization procedures, number of study centers and locations, study setting, study dates, treatments received prior to the study, and treatments administered during the study. Participant characteristics: sample size, mean age, gender, diagnostic criteria, and disease duration; whether participants were on stable antiparkinsonian medication regimens at baseline; timing of outcome assessments relative to medication cycles (e.g. defined 'on' or 'off' states); and use and stability of psychotropic medications. Participant characteristics: sample size, mean age, gender, diagnostic criteria, and disease duration; whether participants were on stable antiparkinsonian medication regimens at baseline; timing of outcome assessments relative to medication cycles (e.g. defined 'on' or 'off' states); and use and stability of psychotropic medications. Intervention characteristics: name of the intervention, number of participants randomized to each intervention, frequency, formulation, and duration. Intervention characteristics: name of the intervention, number of participants randomized to each intervention, frequency, formulation, and duration. Outcomes: primary and secondary outcomes with definitions and time points. For dichotomous data (e.g. adverse events), we will extract the number of participants in each treatment arm who experienced the outcome and the total assessed at the endpoint. For continuous data (e.g. anxiety, depression, health‐related quality of life), we will extract the baseline and final values, standard deviations (SDs), and number of participants assessed in each arm at the endpoint. Outcomes: primary and secondary outcomes with definitions and time points. For dichotomous data (e.g. adverse events), we will extract the number of participants in each treatment arm who experienced the outcome and the total assessed at the endpoint. For continuous data (e.g. anxiety, depression, health‐related quality of life), we will extract the baseline and final values, standard deviations (SDs), and number of participants assessed in each arm at the endpoint. Results: the number of participants allocated to each group, total number analyzed per outcome, group‐level summary data, and the use of intention‐to‐treat (ITT) or per‐protocol (PP) analysis methods. Results: the number of participants allocated to each group, total number analyzed per outcome, group‐level summary data, and the use of intention‐to‐treat (ITT) or per‐protocol (PP) analysis methods. Risk of bias assessment in included studies Two review authors (TFL and JYS) will independently assess risk of bias using the Cochrane RoB 2 tool as outlined in Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions [74]. For cluster or cross‐over RCTs, we will follow the recommendations in Chapter 23 of the Cochrane Handbook for Systematic Reviews of Interventions [75]. We will assess the critical outcomes (i.e. anxiety, depression, and adverse effects) at short‐term (≤ 6 months) and long‐term (> 6 months) follow‐up. We will resolve any discrepancies by consensus, with a third review author (ZL) adjudicating if necessary. We will assess risk of bias across the following domains: bias arising from the randomization process;bias due to deviations from the intended interventions;bias due to missing outcome data;bias in measurement of the outcome;bias in selection of the reported result. bias arising from the randomization process; bias arising from the randomization process; bias due to deviations from the intended interventions; bias due to deviations from the intended interventions; bias due to missing outcome data; bias due to missing outcome data; bias in measurement of the outcome; bias in measurement of the outcome; bias in selection of the reported result. bias in selection of the reported result. We will assess each outcome as low risk of bias, some concerns, or high risk of bias, providing support for each judgment to arrive at an overall risk of bias rating for each outcome. We will use the RoB 2 Excel tool (available at www.riskofbias.info) to implement the assessment. If the risk of bias arises from unpublished data or communication with trialists, we will document this in the risk of bias table. To minimize publication bias and ensure comprehensive coverage, we will actively seek and include unpublished online data when sufficient information is available to allow analysis and risk of bias assessment. The risk of bias assessment will inform the GRADE evaluation and the development of summary of findings tables. Measures of treatment effect Relative treatment effects For continuous outcomes (e.g. anxiety, depression, and health‐related quality of life), we will calculate the mean difference (MD) for outcomes measured with the same instrument, or the standardized mean difference (SMD) for outcomes measured with different instruments, both with 95% confidence intervals (CIs). For dichotomous outcomes (e.g. adverse events), we will calculate the risk ratio (RR) with 95% CIs. Where available, we will refer to published minimal clinically important differences (MCID) for each outcome to interpret clinical relevance. If no established MCID exists, we will use distribution‐based methods (e.g. 0.5*SD) or anchor‐based approaches to estimate meaningful changes. Relative treatment ranking We will assess the relative ranking of interventions using surface under the cumulative ranking curve (SUCRA) values (P‐scores) [76]. The use of P‐scores will allow us, separately for each outcome of interest, to determine which treatment outperforms the largest proportion of its competitors [77]. Unit of analysis issues We will use individual participants as the unit of analysis. If we include studies with designs other than parallel‐group randomized trials (e.g. cross‐over, cluster‐randomized, or multi‐arm trials), we will follow the recommendations in Chapter 23 of the Cochrane Handbook for Systematic Reviews of Interventions [75]. Cross‐over trials: we will analyze data from the first period only.Cluster‐randomized trials: we will use the intracluster correlation coefficient (ICC), if reported, to adjust for cluster effects; if the ICC is unavailable, we will use external estimates from similar studies.Multi‐arm trials: we will combine all relevant experimental and comparator groups into a single experimental and a single comparator group, respectively. If this is not feasible, we will conduct each pair‐wise comparison separately, dividing intervention groups approximately evenly among comparisons. For dichotomous outcomes, we will divide both the number of events and the total participants; for continuous outcomes, we will divide only the total participants, leaving the means and SD unchanged. Cross‐over trials: we will analyze data from the first period only. Cross‐over trials: we will analyze data from the first period only. Cluster‐randomized trials: we will use the intracluster correlation coefficient (ICC), if reported, to adjust for cluster effects; if the ICC is unavailable, we will use external estimates from similar studies. Cluster‐randomized trials: we will use the intracluster correlation coefficient (ICC), if reported, to adjust for cluster effects; if the ICC is unavailable, we will use external estimates from similar studies. Multi‐arm trials: we will combine all relevant experimental and comparator groups into a single experimental and a single comparator group, respectively. If this is not feasible, we will conduct each pair‐wise comparison separately, dividing intervention groups approximately evenly among comparisons. For dichotomous outcomes, we will divide both the number of events and the total participants; for continuous outcomes, we will divide only the total participants, leaving the means and SD unchanged. Multi‐arm trials: we will combine all relevant experimental and comparator groups into a single experimental and a single comparator group, respectively. If this is not feasible, we will conduct each pair‐wise comparison separately, dividing intervention groups approximately evenly among comparisons. For dichotomous outcomes, we will divide both the number of events and the total participants; for continuous outcomes, we will divide only the total participants, leaving the means and SD unchanged. Dealing with missing data We will follow Cochrane recommendations for handling missing data, as described in Chapter 10 of the Cochrane Handbook for Systematic Reviews of Interventions [78]. If individual participant data are missing or unclear, we will contact the authors of the included trials via email to request the missing information. If the authors do not respond, we will apply imputation techniques to replace missing data and treat them as observed. We will calculate missing SD using other reported statistics from the trial (e.g. CIs, standard error (SE), t values, or P values), following the methods described in Chapter 6 of the Cochrane Handbook for Systematic Reviews of Interventions [79]. We will perform sensitivity analyses during meta‐analysis to evaluate the potential impact of missing data. Reporting bias assessment If a meta‐analysis includes 10 or more studies, we will generate funnel plots and perform Egger’s linear regression tests to assess reporting biases, according to Section 12.3 of the Cochrane Handbook for Systematic Reviews of Interventions [80]. Where possible, we will compare eligible trials with their corresponding protocols to evaluate outcome reporting bias. For the network meta‐analysis, we will construct comparison‐adjusted funnel plots to examine the presence of small‐study effects across different treatment comparisons. Synthesis methods Methods for pair‐wise meta‐analysis We will perform conventional pair‐wise meta‐analyses using RevMan software for each comparison and outcome that includes at least two studies, in accordance with Chapters 9 and 10 of the Cochrane Handbook for Systematic Reviews of Interventions [78, 81, 82]. We will calculate 95% CI for all effect measures and display the results graphically in forest plots. We will evaluate the feasibility of meta‐analysis based on the number of available studies and the degree of outcome heterogeneity. We will use an inverse‐variance random‐effects model for all meta‐analyses, as we anticipate clinical and methodological heterogeneity across studies. We will estimate between‐study variance (Tau²) using the Restricted Maximum Likelihood (REML) estimator. When at least three studies contribute to a pooled estimate and the heterogeneity estimate is greater than zero, we will calculate CIs using the Hartung‐Knapp‐Sidik‐Jonkman (HKSJ) method. In pooled analyses of two studies, or when the heterogeneity estimate equals zero, we will apply the Wald‐type method. If data synthesis through meta‐analysis is not feasible, we will apply the Synthesis Without Meta‐analysis (SWiM) approach, as outlined in Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions [80]. Methods for network meta‐analysis We will conduct network meta‐analyses separately for each intervention class. Within each class, we will compare the different interventions. We will conduct separate analyses for short‐term (≤ 6 months) and long‐term (> 6 months) follow‐up outcomes. We will conduct a frequentist network meta‐analysis for each outcome using a random‐effects model implemented through the network suite of commands in Stata 16 [83, 84, 85]. We will estimate the within‐network heterogeneity across comparisons using the REML method [86]. We will combine placebo, waiting‐list control, and usual care into a single comparator node for all analyses. Investigation of heterogeneity and subgroup analysis Pair‐wise meta‐analysis We will assess heterogeneity using the I² statistic, according to the methods described in the Cochrane Handbook for Systematic Reviews of Interventions [78]. We will interpret the I² value as follows: 0% to 40%: might not be important;30% to 60%: may represent moderate heterogeneity;50% to 90%: may represent substantial heterogeneity;75% to 100%: considerable heterogeneity. 0% to 40%: might not be important; 0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity. 75% to 100%: considerable heterogeneity. If I² exceeds 75%, we will consider not pooling the data. If I² is 75% or lower, we will explore potential sources of heterogeneity through subgroup and sensitivity analyses. However, if clinical heterogeneity is present, we will refrain from conducting meta‐analyses. Network meta‐analysis Assessment of the transitivity assumption: before conducting a network meta‐analysis, we will evaluate the transitivity assumption, which posits that effect modifiers are similarly distributed across treatment comparisons within the network [87]. To examine the plausibility of this assumption, we will visually inspect and compare the distributions of potential treatment effect modifiers, such as age, sex, and medication status, across all comparisons. We will also assess the similarity of inclusion and exclusion criteria, including characteristics of participants, treatments, and outcomes, to determine whether these factors may influence treatment effects.Assessment of statistical consistency: we will assess the agreement between direct and indirect evidence by evaluating both local and global inconsistency within the network. We will evaluate each network locally using the loop‐specific method by generating an inconsistency factor and a 95% CI for each closed loop [88]. We will also apply a global assessment for consistency in each network using the design‐by‐treatment interaction model [83]. If any inconsistency is detected, we will follow the guidelines outlined in Chapter 11 of the Cochrane Handbook for Systematic Reviews of Interventions [89]. Assessment of the transitivity assumption: before conducting a network meta‐analysis, we will evaluate the transitivity assumption, which posits that effect modifiers are similarly distributed across treatment comparisons within the network [87]. To examine the plausibility of this assumption, we will visually inspect and compare the distributions of potential treatment effect modifiers, such as age, sex, and medication status, across all comparisons. We will also assess the similarity of inclusion and exclusion criteria, including characteristics of participants, treatments, and outcomes, to determine whether these factors may influence treatment effects. Assessment of the transitivity assumption: before conducting a network meta‐analysis, we will evaluate the transitivity assumption, which posits that effect modifiers are similarly distributed across treatment comparisons within the network [87]. To examine the plausibility of this assumption, we will visually inspect and compare the distributions of potential treatment effect modifiers, such as age, sex, and medication status, across all comparisons. We will also assess the similarity of inclusion and exclusion criteria, including characteristics of participants, treatments, and outcomes, to determine whether these factors may influence treatment effects. Assessment of statistical consistency: we will assess the agreement between direct and indirect evidence by evaluating both local and global inconsistency within the network. We will evaluate each network locally using the loop‐specific method by generating an inconsistency factor and a 95% CI for each closed loop [88]. We will also apply a global assessment for consistency in each network using the design‐by‐treatment interaction model [83]. If any inconsistency is detected, we will follow the guidelines outlined in Chapter 11 of the Cochrane Handbook for Systematic Reviews of Interventions [89]. Assessment of statistical consistency: we will assess the agreement between direct and indirect evidence by evaluating both local and global inconsistency within the network. We will evaluate each network locally using the loop‐specific method by generating an inconsistency factor and a 95% CI for each closed loop [88]. We will also apply a global assessment for consistency in each network using the design‐by‐treatment interaction model [83]. If any inconsistency is detected, we will follow the guidelines outlined in Chapter 11 of the Cochrane Handbook for Systematic Reviews of Interventions [89]. We will appraise clinical heterogeneity by comparing the distribution of participant characteristics, including age, sex, and baseline symptom severity, across studies. For methodological heterogeneity, we will assess study design and implementation factors, including randomization procedures, allocation concealment, blinding of outcome assessment, loss to follow‐up, intervention type, control group type, and outcome measurement instruments. Subgroup analyses In the case of sufficient data, we will perform subgroup analyses based on the following factors. Mean age (≥ 65 years versus < 65 years): evidence indicates that the incidence of anxiety and depressive symptoms among individuals with PD may vary by age [11].Sex (male versus female): evidence suggests that the prevalence and severity of anxiety and depression may differ between men and women with PD [11, 12].Intervention duration (≥ 8 weeks versus < 8 weeks): intervention duration may influence effectiveness, with longer interventions potentially leading to greater improvements in anxiety and depressive symptoms. Mean age (≥ 65 years versus < 65 years): evidence indicates that the incidence of anxiety and depressive symptoms among individuals with PD may vary by age [11]. Mean age (≥ 65 years versus < 65 years): evidence indicates that the incidence of anxiety and depressive symptoms among individuals with PD may vary by age [11]. Sex (male versus female): evidence suggests that the prevalence and severity of anxiety and depression may differ between men and women with PD [11, 12]. Sex (male versus female): evidence suggests that the prevalence and severity of anxiety and depression may differ between men and women with PD [11, 12]. Intervention duration (≥ 8 weeks versus < 8 weeks): intervention duration may influence effectiveness, with longer interventions potentially leading to greater improvements in anxiety and depressive symptoms. Intervention duration (≥ 8 weeks versus < 8 weeks): intervention duration may influence effectiveness, with longer interventions potentially leading to greater improvements in anxiety and depressive symptoms. Equity‐related assessment We will conduct an equity‐related assessment by extracting and reporting data on key equity‐relevant factors, including age, sex, and geographical location, to evaluate the representation of diverse populations across studies. Sensitivity analysis We will conduct sensitivity analyses to examine the impact of the following factors on effect size. Excluding studies with unpublished dataExcluding studies with missing dataExcluding studies in which antiparkinsonian drug regimens were adjusted during the studyExcluding studies that assessed outcomes within the medication cycle rather than at stable time pointsExcluding studies that included participants using psychotropic medicationsExcluding lower‐quality studies (high risk of bias) Excluding studies with unpublished data Excluding studies with unpublished data Excluding studies with missing data Excluding studies with missing data Excluding studies in which antiparkinsonian drug regimens were adjusted during the study Excluding studies in which antiparkinsonian drug regimens were adjusted during the study Excluding studies that assessed outcomes within the medication cycle rather than at stable time points Excluding studies that assessed outcomes within the medication cycle rather than at stable time points Excluding studies that included participants using psychotropic medications Excluding studies that included participants using psychotropic medications Excluding lower‐quality studies (high risk of bias) Excluding lower‐quality studies (high risk of bias) Certainty of the evidence assessment We will generate a summary of findings table following the guidelines outlined in Chapter 14 of the Cochrane Handbook for Systematic Reviews of Interventions [90]. Two review authors (TFL and JYS) will independently assess the certainty of evidence using the GRADE framework, categorizing it as high, moderate, low, or very low. We will resolve any disagreements through discussion or in consultation with a third review author (ZL) if necessary. We will assess the certainty of evidence based on the following domains: risk of bias, imprecision, inconsistency, indirectness, and publication bias. For both direct and indirect comparisons, we will begin our assessment at high certainty. We will assess the certainty of indirect estimates by examining the dominant lowest‐order loop, which we define as the minimal‐order evidence circuit that contributes the largest share of information to the indirect comparison. We will identify this evidence circuit using the contribution matrix, which quantifies how much each direct comparison contributes to each indirect estimate. We will use this information to evaluate the reliability of the indirect evidence. We will assign the certainty rating for an indirect estimate based on the lowest certainty among the direct estimates contributing to that comparison. We will further consider downgrading the certainty of each indirect comparison due to intransitivity if we find that the interventions or populations differ between the direct comparisons informing the loop that contributes most to the indirect estimate. We will rate the certainty of network estimates according to the highest level of certainty among the direct and indirect estimates contributing to each network estimate. We will consider downgrading the certainty of a network estimate if we detect incoherence between indirect and direct estimates, or we observe imprecision [91, 92]. We will prepare separate summary of findings tables for the critical outcomes. We will present the network estimates derived from the network meta‐analysis for short‐term (≤ 6 months) and long‐term (> 6 months) follow‐up in each summary of findings table. We will also indicate the availability of direct evidence (e.g. number of direct comparison studies and participants) or whether the estimates were based on indirect evidence only. We will include the following critical outcomes. Anxiety (measured using validated anxiety scales, such as HARS, BAI)Depression (measured using validated depression scales, such as HDRS, BDI)Adverse effects (as reported by study authors) Anxiety (measured using validated anxiety scales, such as HARS, BAI) Anxiety (measured using validated anxiety scales, such as HARS, BAI) Depression (measured using validated depression scales, such as HDRS, BDI) Depression (measured using validated depression scales, such as HDRS, BDI) Adverse effects (as reported by study authors) Adverse effects (as reported by study authors) Consumer involvement One patient representative and one healthcare professional specializing in geriatric mental health care have provided feedback on outcome selection and intervention relevance. They will also assist in planning the dissemination of review findings, ensuring that the results are communicated clearly and effectively to people living with PD. Supporting Information Supplementary materials are available with the online version of this article: 10.1002/14651858.CD016360. Supplementary materials are published alongside the article and contain additional data and information that support or enhance the article. Supplementary materials may not be subject to the same editorial scrutiny as the content of the article and Cochrane has not copyedited, typeset or proofread these materials. The material in these sections has been supplied by the author(s) for publication under a Licence for Publication and the author(s) are solely responsible for the material. Cochrane accordingly gives no representations or warranties of any kind in relation to, and accepts no liability for any reliance on or use of, such material. Supplementary material 1 Search strategies